DRTS
Alpha Tau Medical Ltd.
NASDAQ · Healthcare · Biotechnology · IL
$12.62
+2.69%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$12.63
From 52W high−18.58%
Volume686930.00
Market cap$1.17B
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataOct 19, 2026
Open
$12.63
From 52W high
−18.58%
Volume
686930.00
Market cap
$1.17B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−22.0x
P/E (TTM)
—
RSI (14)
34.9
MomentumView details →
1D Return
+2.69%
YTD Return
+156.46%
SummaryUpdated Jun 1, 2026
Alpha Tau Medical Ltd. (NASDAQ:DRTS) is a clinical-stage oncology therapeutics company founded in 2015 and headquartered in Jerusalem, Israel. The company went public in March 2021 and focuses on developing innovative radiation therapy technology for treating solid tumors. Alpha Tau's core innovation centers around a proprietary technology called Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy), which represents a novel approach to cancer treatment using radioactive alpha particles delivered directly to tumor sites.
Similar companies
Latest newsMore news →
Alpha Tau Medical completed patient enrollment in its multicenter IMPACT pilot study of Alpha DaRT for unresectable pancreatic cancer, expanding enrollment from 12 to 48 patients.49d agoAlpha Tau Medical reported positive clinical data for Alpha DaRT in combination with pembrolizumab in head and neck cancer at the AHNS conference on July 21, 2026.90d agoAlpha Tau successfully treated the first immunocompromised patient with recurrent cutaneous squamous cell carcinoma in its ADMIRE study at Banner MD Anderson Cancer Center.96d ago